Zita was appointed Non-Executive Director in April 2016 and is Chairman of the Remuneration and Nomination Committee.  Zita’s most recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Frensenius Kabi, a provider of pharmaceutical products and medical devices to hospitals. She played a key role in the sustained development of the company in the Asia Pacific region, achieving double-digit growth and becoming the fastest growing region, contributing around 30% of total company revenue.  Previously, Zita was Vice President of Business Development at CSL Limited, a top 20 ASX biopharmaceutical company focused on developing and marketing protein therapeutics for serious unmet medical diseases.  In 2015, Zita joined the board of two early stage medical technology companies: 4Dx, a company involved in commercialising four-dimensional lung imaging technology; and Bionic Vision Technology, a developer of visual prostheses for patients with retinal degeneration conditions.  Zita currently serves as a Non-Executive Director of Starpharma Holdings, an ASX300 company and a leader in the development of dendrimer products for pharmaceutical, life science and other applications. She also serves on the board of the Vision Eye Institute, Australia’s leading provider of ophthalmic service   

 protein therapeutics